COMPARISON
Dulaglutide vs Tirzepatide
5 attributes held for at least one of the two. 4 differ. Each value carries the register it came from and the date that register was read.
Answer
Dulaglutide is authorised or registered in 10 and Tirzepatide in 10 of the 10 registers read. Dulaglutide: highest phase Phase 4 (after approval). Tirzepatide: highest phase Phase 4 (after approval). 19 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Dulaglutide | Tirzepatide | |
|---|---|---|
| Registered trials differs | 144 clinicaltrials.gov · 2026-10-03 | 309 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: TRULICITY openfda · 2026-10-03T17:23:44.062Z | FDA-approved: MOUNJARO openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation | Authorised ema · 2026-10-03 | Authorised ema · 2026-10-03 |
| EU authorised on differs | 2014-11-21 ema · 2026-10-03 | 2022-09-15 ema · 2026-10-03 |
| ATC code differs | A10BJ05 ema · 2026-10-03 | A10BX16 ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Dulaglutide | placebo | Tirzepatide | placebo |
|---|---|---|---|---|
| Nausea | 14.5% | 5.5% | 25.6% | 8.1% |
| Diarrhoea | 12.8% | 8.5% | 21.2% | 8.3% |
| Constipation | 7.2% | 4.1% | 13.7% | 4.5% |
| Decreased appetite | 7.1% | 2.2% | 11.6% | 2.9% |
| Nasopharyngitis | 11.2% | 10.4% | - | - |
| Urinary tract infection | 10.2% | 9.8% | - | - |
| Back pain | 8.4% | 7.9% | - | - |
| Bronchitis | 7.9% | 8.3% | - | - |
| Hypoglycaemia | 7.5% | 6.6% | - | - |
| Arthralgia | 7.3% | 7.6% | - | - |
| Covid-19 | - | - | 15.5% | 16.0% |
| Vomiting | - | - | 11.4% | 2.6% |
| Dyspepsia | - | - | 7.9% | 2.7% |
| Headache | - | - | 6.6% | 6.2% |
| Abdominal pain | - | - | 6.0% | 2.7% |
| Upper respiratory tract infection | - | - | 5.7% | 6.2% |
Trial register Dulaglutide: 11 placebo-controlled trials; Tirzepatide: 19. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Dulaglutide side effects · Tirzepatide side effects
LEGAL STATUS
Approval in each country read
| Country | Dulaglutide | Tirzepatide | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Authorised | Authorised | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Registered | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Authorised | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
HEAD TO HEAD
19 registered trials include both
| NCT07834398 | Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes COMPLETED · updated 2026-09-22 |
|---|---|
| NCT06779929 | Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes COMPLETED · updated 2026-09-18 |
| NCT07820111 | Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial COMPLETED · updated 2026-09-15 |
| NCT07787936 | GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry NOT_YET_RECRUITING · updated 2026-08-26 |
| NCT07702461 | Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists RECRUITING · updated 2026-07-24 |
| NCT07417618 | INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD) COMPLETED · updated 2026-07-09 |
| NCT04255433 | A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes COMPLETED · updated 2026-07-08 |
| NCT07027969 | Metabolic Surgery for Atrial Fibrillation Elimination NOT_YET_RECRUITING · updated 2026-04-17 |
| NCT07309094 | Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD RECRUITING · updated 2025-12-30 |
| NCT06533527 | Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy COMPLETED · updated 2025-12-05 |
| NCT07088718 | Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data COMPLETED · updated 2025-10-15 |
| NCT07096063 | Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk COMPLETED · updated 2025-10-15 |
| NCT07188545 | Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Rea ACTIVE_NOT_RECRUITING · updated 2025-09-23 |
| NCT05564039 | A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) COMPLETED · updated 2025-08-03 |
| 2022-500101-41-00 | A Phase 4, Randomized, Open-Label, Active-Controlled Study to Investigate the Efficacy and Safety of Switching From Weekly Dulaglutide to Weekly Tirzepatide in Not stated · updated 2024-08-05 |
| NCT02759107 | A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM) COMPLETED · updated 2024-01-16 |
| NCT05990374 | Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years UNKNOWN · updated 2023-08-14 |
| NCT03861052 | A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes COMPLETED · updated 2022-04-14 |
| NCT03131687 | A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus COMPLETED · updated 2019-08-20 |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.